Oxaliplatin infusion-related venous pain: prevention by simultaneous intravenous fluids
| Autor: | J.F.M. Pruijt, Jolien Tol, Stefan van Asten, Britt van Merrienboer, Stefan van Ravensteijn, Mirrian Hilbink |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Side effect medicine.medical_treatment Pain Medicine (miscellaneous) Antineoplastic Agents 03 medical and health sciences 0302 clinical medicine medicine Humans 030212 general & internal medicine Gastrointestinal cancer Infusions Intravenous Vein Aged Retrospective Studies Oncology (nursing) business.industry Incidence (epidemiology) Retrospective cohort study General Medicine Middle Aged medicine.disease Oxaliplatin Medical–Surgical Nursing Glucose medicine.anatomical_structure Peripheral neuropathy 030220 oncology & carcinogenesis Anesthesia Female Colorectal Neoplasms business Central venous catheter medicine.drug |
| Zdroj: | BMJ Supportive & Palliative Care. 11:226-229 |
| ISSN: | 2045-4368 2045-435X |
| DOI: | 10.1136/bmjspcare-2019-002177 |
| Popis: | ObjectiveOxaliplatin is a cytotoxic agent frequently used in the treatment of gastrointestinal cancer patients. A known side effect of oxaliplatin administration via a peripheral vein is infusion-related pain. In this retrospective cohort study we compared the incidence of infusion-related pain in patients treated with oxaliplatin with or without simultaneous fluid infusion (FI) (800 mL glucose 5% in 2 hours).MethodsWe retrospectively defined two cohorts: Patients treated with oxaliplatin and simultaneous intravenous FI and the same number of patients treated without FI.The incidence of infusion-related venous pain was the primary outcome measure. Secondary outcomes included: Incidence of hypersensitivity reactions, infusion time, dose density, number of patients switched to a central venous catheter and incidence of peripheral neuropathy.Results100 patients were included, 50 patients in both groups. Baseline characteristics were comparable, except for age (median 66.8 vs 62.4 years in groups with and without FI; p=0.017), and body mass index (28.0 vs 25.7 kg/m2, respectively; p=0.012). Patients treated with simultaneous FI experienced significantly less vascular pain compared with those without FI (10% vs 78%, respectively; pConclusionConcurrent infusion of 800 mL glucose 5% with peripheral venous administration of oxaliplatin significantly reduces the incidence of infusion-related pain in gastrointestinal cancer patients and is highly feasible and affordable in everyday clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|